ABIO  Arca Biopharma Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Cap.

23.16M

Vuru Grade

49.00/100

Current Price

$2.55
-0.10 (-3.77%)

Stability Price

$9.20
Undervalued by 260.68%

Company Metrics

  • P/E 1.19
  • P/S 0
  • P/B 0.91
  • EPS -1.7
  • Cash ROIC 1,403.45%
  • Cash Ratio 25.80
  • Dividend 0 / 0%
  • Avg. Vol. 32,805.00
  • Shares 6.29M
  • Market Cap. 23.16M

Company Description

ARCA biopharma, Inc., a biopharmaceutical company, engages in the development of genetically-targeted therapies for cardiovascular diseases. Its principal product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure and also for the prevention of atrial fibrillatio... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B ...
Business Wire (press release) - Jan 18, 2017
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the ...
ARCA Biopharma, Inc. (ABIO) Valuation According To Analysts - UK Market News
ARCA Biopharma, Inc. (ABIO) Broker Price Targets For The Coming Week - Fiscal Standard
Arca Biopharma (ABIO) Enters Agreement to Offer Up to $7.3M in Common Stock
StreetInsider.com - Jan 11, 2017
On January 11, 2017, ARCA biopharma, Inc. (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC, as agent (“JonesTrading”), pursuant to which the Company may offer ...
ARCA biopharma Inc (NASDAQ:ABIO) Stock Technicals Hit Strength
CML News - Jan 9, 2017
This is a technical analysis stock rating for ARCA biopharma Inc (NASDAQ:ABIO) . The company has a four bull technical rating which indicates some strength.
Brokers Change Their Target Price On ARCA Biopharma, Inc. (ABIO) - Fiscal Standard
Analysts Update Their Price Target On ARCA Biopharma, Inc. (ABIO) - UK Market News
ARCA biopharma Announces Randomization of First European Patients in GENETIC ...
Business Wire (press release) - Oct 6, 2016
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to the development of genetically-targeted therapies for cardiovascular diseases, today announced ...
ARCA biopharma to Present at Biotech Showcase 2017
Business Wire (press release) - Jan 4, 2017
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will ...
ARCA biopharma to Present at the Dawson James Securities Second Annual Growth ...
Business Wire (press release) - Oct 4, 2016
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will ...
ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides ...
Business Wire (press release) - Nov 14, 2016
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, ...
ARCA biopharma Inc (NASDAQ:ABIO) Upside Stock Technicals at Extreme Strength
CML News - Dec 26, 2016
This is a technical analysis stock rating for ARCA biopharma Inc (NASDAQ:ABIO) . The company has a five bull technical rating which indicates extreme strength.
ARCA biopharma Gains on Fast Track Status for Gencaro
Zacks.com - Apr 14, 2015
ARCA biopharma, Inc. shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro.
ARCA biopharma Announces $37 Million Private Placement
Business Wire (press release) - Jun 11, 2015
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into a securities purchase ...